Periodic Reporting for period 1 - CSC-IS (Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system.)

We screened an initial battery of monoclonal anti-LIFR antibodies generated in mice and rats at the company Aldevron. After the assessment of the antibodies, we identified one with promising biological activity measured as the ability to block the LIF/LIFR-JAK-STAT3 pathway...